Next year, every Medicare drug plan in the country lists Wegovy. Before anyone cheers, every one of those plans also wants a prior authorization. Also today, European regulators have new birth-control advice for people on tirzepatide, and Novo Nordisk shows what lower doses of its combination drug CagriSema did in a phase 3 trial. This is GLP-1 Daily, and it's Monday, November 16. Medicare leads.
From Medcostclear, a data site that counts plans in Medicare's own formulary files:
For 2027, all 5,492 plans list it: 323 of 323 standalone drug plans and 5,169 of 5,169 Medicare Advantage plans with drug coverage. In both years every plan that lists Wegovy requires prior authorization.
For scale, this year it's 175 plans out of 5,496, about three percent, and not one standalone drug plan. So Wegovy goes from almost nowhere to everywhere. The reason is price negotiation. Semaglutide is one of the drugs Medicare negotiated under the Inflation Reduction Act, and the law requires Part D plans to carry negotiated drugs. That price takes effect January 1, 2027: $274 for a 30-day supply, against a $959 list price in 2024. Now the part the headline skips. Part D still doesn't cover GLP-1s for weight loss. A plan listing Wegovy covers it for the uses Part D allows, which under the label means cutting heart attack and stroke risk in adults with established heart disease and obesity or overweight, or MASH, a fatty liver disease with moderate to advanced scarring. And that $274 is what the manufacturer must make available to pharmacies, not your copay. Your cost depends on your plan. In the 2027 files, 5,369 plans also set a quantity limit, and none use step therapy. Zepbound, for comparison, shows up on seven plans. So if you need Wegovy for weight management alone, your route is still the Medicare GLP-1 Bridge, the fifty-dollar program we've been following, which runs through December 31, 2027. Two caveats about the source. It counts plans, not people, and the site says the page was compiled by AI from CMS files. It isn't a CMS announcement. If you're on Medicare, ask your prescriber whether your diagnosis fits one of the covered uses before you count on that listing.
The Diabesity Rounds Desk, summarizing last week's meeting of the European Medicines Agency's human medicines committee:
Women using an oral contraceptive are now advised to do one of two things. They can add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Or they can switch to a non-oral method of contraception.
The drug is Mounjaro, tirzepatide. The committee met November 9 through 12, the highlights came out Friday, and this is a formal communication to healthcare professionals. Notice how carefully it's worded. The EMA says limited information is available on how tirzepatide affects oral contraceptives in women with obesity, overweight or type 2 diabetes. The highlights don't put a size on any effect. But the practical windows are clear: the first four weeks, and four weeks after every dose step. Those are the weeks when a new patient is juggling a new routine, and birth control is easy to forget about. This is European guidance, and the report says nothing about American labeling. If you could become pregnant and you're on tirzepatide or considering it, bring up contraception with your prescriber at your next visit, and make that the place any change gets decided.
Medscape, in a conference report edited by Maria Turner:
Patients with overweight or obesity who received lower doses of the investigational drug CagriSema (Novo Nordisk) — 1.7 mg /1.7 mg and 1.0 mg/1.0 mg instead of the 2.4 mg/2.4 mg used in previous trials of the drug — had an estimated average weight loss of more than 20% for both doses at 68 weeks vs 2% with placebo, according to primary results of the small phase 3 REDEFINE 9 trial.
CagriSema pairs semaglutide, the drug in Wegovy, with cagrilintide, an amylin analog. The results were presented Saturday at ObesityWeek in Washington and published in The Lancet Diabetes and Endocrinology. So, the evidence grade. 309 adults at 24 sites in five countries, none with diabetes, and the trial was funded by Novo Nordisk. Those 20.7 and 21 percent figures assume everyone stayed on the drug. Counting everyone regardless of stopping, it's 19.4 and 18.6 percent, against 4.6 on placebo. And the trial wasn't powered to compare the two doses, so the smaller dose edging out the bigger one by three tenths of a point tells you nothing. Side effects were mostly gastrointestinal and mild to moderate. Adverse events led 2.9 and 4.9 percent of people on the two doses to stop treatment, versus 4.9 percent on placebo. CagriSema is not approved in the United States. Novo filed for the 2.4 milligram dose in December 2025 and says it expects an FDA decision this quarter. Nobody in these reports mentions a price, or who will cover it. Read it as a company-funded trial in a peer-reviewed journal: real data, small sample, no approval. When there's something to prescribe, that's the moment to ask your clinician whether it fits you.
If this briefing saves you a few tabs of reading each morning, a rating or a short review in your podcast app is how other patients stumble onto it. It takes about a minute.
Before tomorrow's episode, we'll keep an eye on ObesityWeek and the FDA's pending CagriSema decision. Questions about your own treatment belong with the clinician who prescribes it, not with us. GLP-1 Daily is one of the Lantern Podcasts, and we're back Tuesday, November 17.